Abstract
INTRODUCTION: in Colombia the guide 412 for hypertension and type 2 diabetes is followed through to treat and to avoid complications of the cardiovascular disease; which represents an important cause of morbility and mortality in adults.
MATERIALS AND METHODS: a cross-sectional descriptive study was done on cardiovascular risk patients that attended to control in an institution of first level of attention to give a real vision of the form as the guide is applied. A group of 306 attending patients to monthly control by diagnosis of determining diseases of cardiovascular risk was set. With base in the implemented guide and up-to-date literature of the subject the variables and the control goals were set .The clinical history of each patient was reviewed and data of interest was extracting for later analysis.
RESULTS: the hypertension appeared in 89% of the patients and the type 2 diabetes in 10%, the associated factors of risk like family history of cardiovascular disease, alcoholism, smoking, physical inactivity, overweight, were not addressed suitably; The 53,9% of the hypertensive ones were controlled and the 9,1% have optimum control of hypertension and metabolic factors; The attendance to monthly control never reached 70%.
DISCUSSION AND CONCLUSIONS: the cardiovascular risk group has been increased in possibly parallel number of patients to the implementation of the new social security system in health; although the attendance and the methodology of the monthly controls have many limitations, this has showed positive results that determine according to Literature diminution of mortality of the community.
Key words: Cardiovascular risk. Hypertension. Type 2 diabetes.
References
2. Pinilla AE, Lancheros L, Viasus DF, Agudelo C, Pardo R, Gaitan H, et al. Ministerio de la Protección Social, Programa de Apoyo a la Reforma de Salud, Guías de promoción de la salud y prevención de enfermedades en la salud pública. Guía de atención de la diabetes mellitus tipo 2. Bogotá, Colombia. Mayo 2007:361-440.
3. Congreso de la república de Colombia. Ley 100 por la cual se crea el sistema de seguridad social integral y se dictan otras disposiciones. Colombia. 1993.
4. Ruiz AJ. Manual de diagnóstico y tratamiento de las dislipidemias. Ruiz AJ editor. Enfermedad coronaria en América Latina. 1 ed. Bogotá, Colombia: AstraZeneca; 2007. p. 9-19.
5. Mendivil CO, Garragueta M, Sierra ID. Hacia el manejo practico de las dislipidemias. Interpretación del perfil lipidico y evaluación del riesgo cardiovascular global. 2a ed. Bogotá, Colombia: TC impresores; 2007. p. 27-32.
6. Mancia G, Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Grupo de trabajo para el manejo de la hipertensión arterial de la sociedad europea de hipertensión y la sociedad europea de cardiología. Guía de 2007 para el manejo de la hipertensión arterial. Journal of Hypertension 2007;25:1105-87.
7. Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Horward J, et al. Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 2I). NIH Publication 2002;5202-15.
8. Padwal RS, Hemmelgarn BR, Khan NA, Grover S, McAlister FA, McKay DW, et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. Can J, Cardiol 2008; 24(6):455-63.
9. Khan NA, Hemmelgarn B, Herman RJ, Rabkin SW, McAlister FA, Bell CM, et al. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 – therapy. Can J Cardiol 2008;24(6):465-75.
10. Cheng AY. Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel 2I guidelines. Current Opinion in Cardiology 2006;21:400–4.
11. Marulanda MI. Manual de diagnóstico y tratamiento de las dislipidemias. Ruiz AJ editor. Definición de metas terapéuticas. 1a ed. Bogotá, Colombia: AstraZeneca; 2007. p. 66-71.
12. Navarrete S. Huertas D. Rozo LE. Ospina JE. Prevalencia de factores de riesgo para enfermedad cardiovascular en una muestra de pacientes con hipertensión arterial esencial: estudio descriptivo. Rev. Colom. Cardiol 2009;16(2):64-70.
13. Fajardo HA, Gutiérrez A, Navarrete S, Barrera J. Prevalencia factores de riesgo cardiovascular. Localidad de los Mártires. Bogotá, Colombia. Universidad Nacional de Colombia. Revista Facultad de Medicina 2003;51(4):198-202.
14. Barrera E, Cerón N, Ariza M. Conocimiento y factores de riesgo cardiovascular y su relación con la presencia de hipertensión arterial. Colombia Med 2000;31:20-2.
15. Rodríguez JM, Daudinot S, Acosta EB, Mora SR, Et al. Influencia de factores de riesgo cardiovascular en el control clínico de la hipertensión arterial. Rev Cubana Med Milit 2005;34(3).
16. Bonet A, Navarro J, Puertas A, Valdivieso C, Pau S, Tortola D, et al. Control de factores de riesgo cardiovascular en pacientes diabéticos atendidos en dos equipos de Atención Primaria y costes directos asociados. Parte I: Valoración del riesgo cardiovascular. Medifam 2002;12(8).
17. King AB. Wolfe GS. Evaluation of a diabetes specialist–guided primary care diabetes treatment program. Journal of the American Academy of Nurse Practitioners 2009;21:24–30.
18. Lima NK, Abbasi F, Lamendola C, Reaven GM. Prevalence of Insulin Resistance and Related Risk Factors for Cardiovascular Disease in Patients with Essential Hypertension. American Journal of Hypertension 2009; 22(1):106-11.
19. Campbell NRC, Leiter LA, Larochelle P, Tobe S, Chockalingam A, Ward R, et al. Hypertension in diabetes: A call to action. Can J Cardiol 2009;25(5):299-302.
20. Firdaus M, Asbury J, Reynolds DW. A new paradigm of cardiovascular risk factor modification. Vascular Health and Risk Management 2005;1(2):101-9.